Suppliers and packagers for generic pharmaceutical drug: LENIOLISIB PHOSPHATE

LENIOLISIB PHOSPHATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pharming	JOENJA	leniolisib phosphate	TABLET;ORAL	217759	NDA	Pharming Healthcare Inc.	71274-170-60	1 BOTTLE, PLASTIC in 1 CARTON (71274-170-60) / 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC	2023-03-29

Leniolisib Phosphate Suppliers: Who Manufactures API, Drug Product, and Key Components for PI3Kδ Inhibitor Supply Chains

Last updated: June 3, 2026

Leniolisib phosphate supply is handled through a multi-tier model: a branded R&D originator/marketer supplies the commercial product, while separate upstream vendors manufacture the leniolisib active pharmaceutical ingredient (API) and the final drug product (tablet fill-finish and packaging). The supplier map for leniolisib phosphate is established via regulatory filings (drug master files, facility listings), Good Manufacturing Practice inspections, and procurement disclosures tied to marketed distribution.

H1: Leniolisib Phosphate Suppliers for API, Drug Product, and Commercial Manufacturing

Who supplies leniolisib phosphate API (active pharmaceutical ingredient)?

The API supply chain for leniolisib phosphate typically centers on dedicated chemical synthesis and crystallization partners that produce leniolisib free base and then convert to the phosphate salt under controlled steps (salt formation, isolation, drying, and particle-size conditioning).

What does API procurement usually require for leniolisib phosphate?

• Salt-forming and isolation capability for the phosphate form
• Control of polymorph/crystal habit, residual solvents, water content, and particle size
• Analytics scope: HPLC/UPLC, LC-MS impurity profiling, phosphates assay, and solid-state characterization

Which API manufacturers are in scope for leniolisib phosphate?

Only suppliers that are named in regulator-accessible listings (e.g., EMA/FDA drug product labeling facility data where available), or that appear in dossier documentation referenced by marketed product listings, qualify for a defensible “supplier” identification. Without those exact, citable facility assignments, supplier naming risks being incorrect.

Who manufactures leniolisib phosphate drug product (tablets) for commercial distribution?

Commercial supply of leniolisib phosphate requires formulation development and finished-dose manufacturing for tablets, including blending, granulation (if applicable), compression, coating, and quality release.

What drug-product capabilities matter for leniolisib phosphate tablets?

• Solid oral dose manufacturing capacity (tablet compression and coating)
• Batch release testing for dissolution and impurities
• Packaging configuration aligned to marketed presentation and stability zones

Which finished-dose manufacturers are in scope?

A correct answer requires the finished-dose manufacturing site(s) and packager(s) tied to the specific marketed NDC/MAH-labeled product. Those are determined from labeling/manufacturer sections and regulatory facility references.

What companies supply leniolisib phosphate under contract manufacturing (CDMO/CMO)?

For small-molecule oncology drugs like leniolisib, contract manufacturing is common across:

1. API synthesis and salt formation
2. Drug substance-to-drug product conversion
3. Primary/secondary packaging

What is the usual contract manufacturing split?

• API and salt conversion: specialized chemical manufacturers
• Drug product: tablet-specific CDMO with compressed schedule release testing
• Packaging: local packaging partners for region-specific distribution

Which contract manufacturers supply leniolisib phosphate?

Supplier identification must be tied to citable site data (facility name on regulatory product labeling, EMA/FDA facility listing, or validated dossier references). Without those citable facility-level assignments, naming specific companies cannot be done accurately.

What is the Orange Book status of leniolisib phosphate, and how does it affect supplier landscape?

Leniolisib is not a typical US generic “Orange Book” situation because the therapeutic area and regulatory pathway often place the product outside the traditional small-molecule generic expectation for Orange Book listings. If the listed product is not in the Orange Book, the dataset that normally links brands to ANDA generics and patent listings is not the controlling framework.

What this means for suppliers

• If Orange Book coverage is absent or limited, the supplier landscape is defined more by branded supply chain and CDMO capacity than by ANDA-qualified facility networks.
• The strongest procurement intelligence still comes from product labeling manufacturing and packaging sections, not from patent list matching.

When do leniolisib phosphate exclusivity and patent expirations change supplier dynamics?

Supplier dynamics shift most when:

• Regulatory exclusivity expires (preventing certain follow-on approvals)
• Patent estates narrow around key claims (formulation, salt, polymorph, method-of-use)

How do patent expiry dates affect sourcing?

• API supply may remain with the branded-chain vendors if manufacturing is tightly tied to solid-state specs and validated analytics.
• Generic or follow-on approvals (if any) drive new qualification batches and alternative CMOs.

What are the specific expiry timelines for leniolisib phosphate?

A precise timeline requires the actual patent and exclusivity record for the marketed product in each jurisdiction, plus any patent term adjustments and pediatric exclusivity. Without those citable records, an expiry timeline cannot be stated.

What generic entry risks exist for leniolisib phosphate that would add suppliers?

New suppliers usually appear only when:

• A generic or follow-on product is approved (ANDA or other pathway)
• The dossier includes demonstrated equivalence and the same critical quality attributes (CQAs) for the phosphate salt

What generic scenarios add API and tablet suppliers?

• Generic API manufacturers qualify a phosphate salt process
• Drug product CMOs qualify tablet formulations meeting dissolution and impurity specs
• Packaging partners scale distribution to the generic launch volumes

What this implies for current suppliers

Absent approved follow-on products, the supplier base stays near the originator’s validated manufacturing network.

How does leniolisib phosphate compare with other PI3Kδ inhibitors in supplier concentration?

Within PI3Kδ inhibitor classes, supplier concentration often reflects:

• Proprietary solid-state control strategies for salts and polymorphs
• Tight QA/QC controls for trace impurities
• Smaller production volumes relative to blockbuster oral agents

What supply chain pattern is common across this class?

• Fewer API vendors than the average large-molecule oral drug
• More reliance on specialized salt formation and solid-state CDMOs
• Tablet CMOs selected for scale-out speed and stability control

Key constraints on identifying suppliers for leniolisib phosphate

Accurate “who supplies” answers depend on facility-level data that is not contained in the query text. Supplier identification must map to:

• Drug product label manufacturer and packager
• API manufacturer names tied to drug substance documentation
• Regulatory facility listings that specify the manufacturing site(s)

Without citable facility assignments tied to leniolisib phosphate, naming specific companies would create factual exposure.

Key Takeaways

• Leniolisib phosphate supply is governed by facility-qualified API salt formation and tablet drug product manufacturing networks.
• Supplier identification must be anchored to regulatory label and facility-level listings (drug product manufacturer, API site, and packager) to be accurate.
• Exclusivity and patent estate windows influence whether new API and tablet suppliers appear via generic or follow-on approvals.

FAQs

1. Which manufacturing sites produce leniolisib phosphate tablets?
2. Who manufactures leniolisib phosphate API (including phosphate salt formation)?
3. Do leniolisib phosphate tablets have multiple approved packaging configurations and packagers?
4. How do patent claims around solid form (polymorph/salt) affect alternative supplier qualification?
5. When do new CDMOs typically enter leniolisib phosphate supply after regulatory follow-on approvals?

References

1. (No citable sources provided in the prompt.)